Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Catarina Falcão de Campos & Isabel Conceição. (2023) Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy. Drug, Healthcare and Patient Safety 15, pages 51-62.
Read now
Read now
Teresa Coelho, Isabel Conceição, Márcia Waddington-Cruz, Denis Keohane, Marla B. Sultan, Doug Chapman & Leslie Amass. (2022) A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS). Amyloid 29:4, pages 228-236.
Read now
Read now
Arianna Burton, Adam Castaño, Marianna Bruno, Steve Riley, Jennifer Schumacher, Marla B Sultan, Sandi See Tai, Daniel P Judge, Jignesh K Patel & Jeffery W Kelly. (2021) Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. Drug Design, Development and Therapy 15, pages 1225-1243.
Read now
Read now
Matthias N. Ungerer, Ernst Hund, Jan C. Purrucker, Laura Huber, Christoph Kimmich, Fabian aus dem Siepen, Selina Hein, Arnt V. Kristen, Katrin Hinderhofer, Jennifer Kollmer, Stefan Schönland, Ute Hegenbart & Markus Weiler. (2021) Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience. Amyloid 28:2, pages 91-99.
Read now
Read now
Ola Akinboboye, Keyur Shah, Alberta L. Warner, Thibaud Damy, Herman A. Taylor, Jared Gollob, Christine Powell, Verena Karsten, John Vest & Mathew S. Maurer. (2020) DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis. Amyloid 27:4, pages 223-230.
Read now
Read now
Maria C. Azevedo Coutinho, Nuno Cortez-Dias, Guilhermina Cantinho, Susana Gonçalves, Miguel Nobre Menezes, Tatiana Guimarães, Gustavo Lima da Silva, Ana Rita Francisco, João Agostinho, Laura Santos, Isabel Conceição & Fausto J. Pinto. (2020) The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease. Amyloid 27:3, pages 174-183.
Read now
Read now
Elissa Driggin, Stephen Helmke, Jeffeny De Los Santos, Sergio Teruya, Samantha Guadalupe, Jeff Goldsmith & Mathew S. Maurer. (2020) Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotype. Amyloid 27:2, pages 73-80.
Read now
Read now
Isabel Conceição, Teresa Coelho, Claudio Rapezzi, Yeşim Parman, Laura Obici, Lucía Galán & Antoine Rousseau. (2019) Assessment of patients with hereditary transthyretin amyloidosis – understanding the impact of management and disease progression. Amyloid 26:3, pages 103-111.
Read now
Read now
Jonah Rubin, Julissa Alvarez, Sergio Teruya, Adam Castano, Ronald A. Lehman, Mark Weidenbaum, Jeffrey A. Geller, Stephen Helmke & Mathew S. Maurer. (2017) Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?. Amyloid 24:4, pages 224-228.
Read now
Read now
Hirofumi Jono & Yukio Ando. (2017) Towards targets and treatments in transthyretin amyloidosis. Expert Opinion on Orphan Drugs 5:9, pages 691-699.
Read now
Read now
Fabio A. Barroso, Daniel P. Judge, Ben Ebede, Huihua Li, Michelle Stewart, Leslie Amass & Marla B. Sultan. (2017) Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 24:3, pages 194-204.
Read now
Read now
Denis Keohane, Jeffrey Schwartz, Balarama Gundapaneni, Michelle Stewart & Leslie Amass. (2017) Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid 24:1, pages 30-36.
Read now
Read now
Articles from other publishers (62)
Helena F. Pernice & Katrin Hahn. (2023) Neurologische Manifestationen der ATTR-AmyloidoseNeurological manifestations of ATTR amyloidosis. Die Innere Medizin 64:9, pages 848-854.
Crossref
Crossref
Deandre King, K. H. Vincent Lau & Michelle C. Kaku. (2023) Treatment Updates for Neuropathy in Hereditary Transthyretin Amyloidosis. Current Treatment Options in Neurology 25:6, pages 137-149.
Crossref
Crossref
Amir Dori, Michael Arad, Yishay Wasserstrum, Arthur Pollak, Vera Nikitin, Merav Ben‐David, Jana Shamash, Ayelet Hashachar Nahum, Efrat Shavit‐Stein, Liran Domachevsky, Rafael Kuperstein, Dan Dominissini, Natalia Shelestovich, Menachem Sadeh, Elon Pras & Lior Greenbaum. (2023)
Ser77Tyr
transthyretin amyloidosis in Israel: Initial manifestations and diagnostic features
. Annals of Clinical and Translational Neurology 10:4, pages 553-567.
Crossref
Crossref
Marcus Vinicius Pinto, Marcondes Cavalcante FrançaJrJr, Marcus Vinicius Magno Gonçalves, Marcela Câmara Machado-Costa, Marcos Raimundo Gomes de Freitas, Francisco de Assis Aquino Gondim, Carlo Domenico Marrone, Alberto Rolim Muro Martinez, Carolina Lavigne Moreira, Osvaldo J. M. Nascimento, Anna Paula Paranhos Covaleski, Acary Souza Bulle de Oliveira, Camila Castelo Branco Pupe, Marcia Maria Jardim Rodrigues, Francisco Tellechea Rotta, Rosana Herminia Scola, Wilson MarquesJrJr & Márcia Waddington-Cruz. (2023) Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition. Arquivos de Neuro-Psiquiatria 81:03, pages 308-321.
Crossref
Crossref
Mayara Gabriele Toledo, Diane Xavier de Ávila, Eduarda Corrêa Maia & Evandro Tinoco Mesquita. 2023. Amyloidosis and Fabry Disease. Amyloidosis and Fabry Disease
437
448
.
Miglena Smerikarova, Stanislav Bozhanov, Vania Maslarska & Ivailo Tournev. (2022) Determination of Tafamidis Plasma Concentrations in Amyloidosis Patients with Glu89Gln Mutation by HPLC-UV Detection. Journal of Chromatographic Science 60:9, pages 840-847.
Crossref
Crossref
Chafic Karam, Duncan Brown, Min Yang, Nicolae Done, Ibou Dieye, Ana Bozas, Montserrat Vera Llonch & James Signorovitch. (2022)
Factors associated with increased
health‐related
quality‐of‐life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen
. Muscle & Nerve 66:3, pages 319-328.
Crossref
Crossref
Antonia Carroll, P James Dyck, Mamede de Carvalho, Marina Kennerson, Mary M Reilly, Matthew C Kiernan & Steve Vucic. (2022) Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. Journal of Neurology, Neurosurgery & Psychiatry 93:6, pages 668-678.
Crossref
Crossref
Jan M. Griffin, Eleonore Baughan, Hannah Rosenblum, Kevin J. Clerkin, Justin A. Fried, Jayant Raikhelkar, Nir Uriel, Thomas H. Brannagan, Koji Takeda, Justin L. Grodin, Charles Marboe, Mathew S. Maurer & Maryjane A. Farr. (2022) Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. The Journal of Heart and Lung Transplantation 41:2, pages 199-207.
Crossref
Crossref
S. S. Nikitin, S. N. Bardakov, N. A. Suponeva, I. V. Zhirov, T. A. Adyan, D. A. Grishina & R. V. Deev. (2021) Phenotypic heterogeneity and diagnostic features of transthyretin amyloidosis with polyneuropathy. Neuromuscular Diseases 11:3, pages 12-36.
Crossref
Crossref
Laura Obici & Roberta Mussinelli. (2021) Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future. Neurotherapeutics 18:4, pages 2286-2302.
Crossref
Crossref
Maike F. Dohrn, Michaela Auer-Grumbach, Ralf Baron, Frank Birklein, Fabiola Escolano-Lozano, Christian Geber, Nicolai Grether, Tim Hagenacker, Ernst Hund, Juliane Sachau, Matthias Schilling, Jens Schmidt, Wilhelm Schulte-Mattler, Claudia Sommer, Markus Weiler, Gilbert Wunderlich & Katrin Hahn. (2020) Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature. Journal of Neurology 268:10, pages 3610-3625.
Crossref
Crossref
Peter Špalek. (2021) Orphan drugs in treatment of rare neuromuscular disorders. Neurologie pro praxi 22:2, pages 104-112.
Crossref
Crossref
Xin Jiang, Richard Labaudinière, Joel N. Buxbaum, Cecília MonteiroMarta Novais, Teresa CoelhoJeffery W. Kelly. (2021) A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Proceedings of the National Academy of Sciences 118:9.
Crossref
Crossref
Maike F. Dohrn, Sandra Ihne, Ute Hegenbart, Jessica Medina, Stephan L. Züchner, Teresa Coelho & Katrin Hahn. (2020) Targeting transthyretin ‐ Mechanism‐based treatment approaches and future perspectives in hereditary amyloidosis. Journal of Neurochemistry 156:6, pages 802-818.
Crossref
Crossref
Diana Bonderman. (2021)
How to
ATTR‐ACT
the perfect match?
. European Journal of Heart Failure 23:2, pages 275-276.
Crossref
Crossref
Evan T. Powers & Jeffery W. Kelly. 2021. Neurotherapeutics in the Era of Translational Medicine. Neurotherapeutics in the Era of Translational Medicine
65
103
.
Massimo Russo, Luca Gentile, Antonio Toscano, M’Hammed Aguennouz, Giuseppe Vita & Anna Mazzeo. (2020) Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects. Brain Sciences 10:12, pages 952.
Crossref
Crossref
Valentina Loconte, Michele Cianci, Ilaria Menozzi, Davide Sbravati, Francesco Sansone, Alessandro Casnati & Rodolfo Berni. (2020) Interactions of tolcapone analogues as stabilizers of the amyloidogenic protein transthyretin. Bioorganic Chemistry 103, pages 104144.
Crossref
Crossref
Peter A. Lockwood, Vu H. Le, Melissa T. O'Gorman, Terrell A. Patterson, Marla B. Sultan, Ekaterina Tankisheva, Qiang Wang & Steve Riley. (2020) The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers. Clinical Pharmacology in Drug Development 9:7, pages 849-854.
Crossref
Crossref
Ellen Y. Cotrina, Ângela Oliveira, José Pedro Leite, Jordi Llop, Luis Gales, Jordi Quintana, Isabel Cardoso & Gemma Arsequell. (2020) Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer. International Journal of Molecular Sciences 21:19, pages 7166.
Crossref
Crossref
Tomonori Ishii, Yoko Hirano, Noriko Matsumoto, Ami Takata, Yoshiki Sekijima, Mitsuharu Ueda & Yukio Ando. (2020) Characteristics of Patients with Hereditary Transthyretin Amyloidosis and an Evaluation of the Safety of Tafamidis Meglumine in Japan: An Interim Analysis of an All-case Postmarketing Surveillance. Clinical Therapeutics 42:9, pages 1728-1737.e6.
Crossref
Crossref
M. Schilling, M. Auer-Grumbach, R. Baron, F. Birklein, F. Escolano-Lozano, M. F. Dohrn, C. Geber, N. Grether, T. Hagenacker, K. Hahn, H. C. Lehmann, J. Sachau, J. Schmidt, W. Schulte-Mattler, C. Sommer, M. Weiler & E. Hund. (2020) Hereditäre Transthyretinamyloidose (ATTRv-Amyloidose)Hereditary transthyretin amyloidosis (ATTRv amyloidosis). DGNeurologie 3:5, pages 369-383.
Crossref
Crossref
Héctor Cristóbal Gutiérrez, Ana Lara Pelayo-Negro, David Gómez Gómez, Miguel Ángel Martín Vega & Marta Valero Domínguez. (2020) Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review. European Journal of Hospital Pharmacy 27:4, pages 194-201.
Crossref
Crossref
Laura Obici & David Adams. (2020) Acquired and inherited amyloidosis: Knowledge driving patients' care. Journal of the Peripheral Nervous System 25:2, pages 85-101.
Crossref
Crossref
Concetta Di Nora & Ugolino Livi. (2020) Heart transplantation in cardiac storage diseases: data on Fabry disease and cardiac amyloidosis. Current Opinion in Organ Transplantation 25:3, pages 211-217.
Crossref
Crossref
Fabiola Escolano-Lozano, Christian Geber, Ana Paula Barreiros & Frank Birklein. (2020) Follow-up in transthyretin familial amyloid polyneuropathy: Useful investigations. Journal of the Neurological Sciences 413, pages 116776.
Crossref
Crossref
Giampaolo Merlini, Teresa Coelho, Márcia Waddington Cruz, Huihua Li, Michelle Stewart & Ben Ebede. (2020) Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years. Neurology and Therapy 9:1, pages 105-115.
Crossref
Crossref
Taichi Nomura, Yuki Oshima, Masanao Yoshino, Masaaki Matsushima, Ichiro Yabe & Hidenao Sasaki. (2020) Two elderly cases of transthyretin amyloid polyneuropathy without a family history高齢発症で家族歴の明らかではない遺伝性トランスサイレチン型アミロイドポリニューロパチーの2例. Rinsho Shinkeigaku 60:10, pages 688-692.
Crossref
Crossref
Saša A Živković. (2020) Neuropathy Associated with Hereditary Transthyretin Amyloidosis—Diagnosis and Management. US Neurology 16:2, pages 103.
Crossref
Crossref
Valentina Loconte, Ilaria Menozzi, Alberto Ferrari, Claudia Folli, Bruno P. Imbimbo, Giuseppe Zanotti & Rodolfo Berni. (2019) Structure-activity relationships of flurbiprofen analogues as stabilizers of the amyloidogenic protein transthyretin. Journal of Structural Biology 208:2, pages 165-173.
Crossref
Crossref
Márcia Waddington Cruz. (2019) Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review. Clinical Autonomic Research 29:S1, pages 19-24.
Crossref
Crossref
David Adams, Haruki Koike, Michel Slama & Teresa Coelho. (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nature Reviews Neurology 15:7, pages 387-404.
Crossref
Crossref
Yvette N. Lamb & Emma D. Deeks. (2019) Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy. Drugs 79:8, pages 863-874.
Crossref
Crossref
Lorena Saelices, Binh A. Nguyen, Kevin Chung, Yifei Wang, Alfredo Ortega, Ji H. Lee, Teresa Coelho, Johan Bijzet, Merrill D. Benson & David S. Eisenberg. (2019) A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils. Journal of Biological Chemistry 294:15, pages 6130-6141.
Crossref
Crossref
Giuseppe Vita, Gian Luca Vita, Claudia Stancanelli, Luca Gentile, Massimo Russo & Anna Mazzeo. (2019) Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. Neurological Sciences 40:4, pages 661-669.
Crossref
Crossref
Giorgio Colombo, Emanuele Frattini, Elisa Ceriani, Massimo Zilocchi, Roberto Del Bo, Alessio DI Fonzo & Monica Solbiati. (2018) Syncope and autonomic failure in a middle-aged man. Internal and Emergency Medicine 14:2, pages 271-274.
Crossref
Crossref
Josef Finsterer, Stephan Iglseder, Julia Wanschitz, Raffi Topakian, Wolfgang N. Löscher & Wolfgang Grisold. (2019) Hereditary transthyretin-related amyloidosis. Acta Neurologica Scandinavica 139:2, pages 92-105.
Crossref
Crossref
Pooja Raibagkar & Nagagopal Venna. 2019. Neurorheumatology. Neurorheumatology
249
258
.
Leslie Amass, Huihua Li, Balarama K. Gundapaneni, Jeffrey H. Schwartz & Denis J. Keohane. (2018) Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy. Orphanet Journal of Rare Diseases 13:1.
Crossref
Crossref
Yoshiki Sekijima, Mitsuharu Ueda, Haruki Koike, Sonoko Misawa, Tomonori Ishii & Yukio Ando. (2018) Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet Journal of Rare Diseases 13:1.
Crossref
Crossref
Teresa CoelhoMónica InêsIsabel ConceiçãoMarta SoaresMamede de CarvalhoJoão Costa. (2018) Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology 91:21.
Crossref
Crossref
Johanna Vollmar, Julia C. Schmid, Maria Hoppe-Lotichius, Ana P. Barreiros, Mimoun Azizi, Tilman Emrich, Christian Geber, Arno Schad, Veronica Weyer, Gerd Otto, Michael Heise, Jens Mittler, Frank Birklein, Hauke Lang, Peter R. Galle & Tim Zimmermann. (2018) Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study. Transplant International 31:11, pages 1207-1215.
Crossref
Crossref
I. Conceição, B. Miranda, J. Castro & M. de Carvalho. (2018) Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients. European Journal of Neurology 25:11, pages 1320-e115.
Crossref
Crossref
Laura Obici. (2018) Becoming familiar with hereditary transthyretin amyloidosis, a treatable neuropathy. Arquivos de Neuro-Psiquiatria 76:9, pages 573-574.
Crossref
Crossref
Marcus Vinicius Pinto, Amilton Antunes Barreira, Acary Souza Bulle, Marcos Raimundo Gomes de Freitas, Marcondes Cavalcante França Jr, Francisco de Assis Aquino Gondim, Carlo Domenico Marrone, Wilson Marques Jr, Osvaldo J. M. Nascimento, Francisco Tellechea Rotta, Camila Pupe & Márcia Waddington-Cruz. (2018) Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy. Arquivos de Neuro-Psiquiatria 76:9, pages 609-621.
Crossref
Crossref
Scot Walker. (2018) New Medications in the Treatment of Hereditary Transthyretin Amyloidosis. Hospital Pharmacy 53:4, pages 236-238.
Crossref
Crossref
Rajiv Mundayat, Michelle Stewart, Jose Alvir, Sarah Short, Moh-Lim Ong, Denis Keohane, Denise Rill & Marla B. Sultan. (2018) Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurology and Therapy 7:1, pages 87-101.
Crossref
Crossref
Daniel Serrano, Christopher B. Atzinger & Marc F. Botteman. (2018) Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches. Neurology and Therapy 7:1, pages 141-154.
Crossref
Crossref
Qian Chen, Lamei Yuan, Xiong Deng, Zhijian Yang, Shengwang Zhang, Sheng Deng, Hongwei Lu & Hao Deng. (2017) A Missense Variant p.Ala117Ser in the Transthyretin Gene of a Han Chinese Family with Familial Amyloid Polyneuropathy. Molecular Neurobiology 55:6, pages 4911-4917.
Crossref
Crossref
Hannah RosenblumAdam CastanoJulissa AlvarezJeff GoldsmithStephen HelmkeMathew S. Maurer. (2018) TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis. Circulation: Heart Failure 11:4.
Crossref
Crossref
Violaine Plante-Bordeneuve. (2017) Transthyretin familial amyloid polyneuropathy: an update. Journal of Neurology 265:4, pages 976-983.
Crossref
Crossref
B. K. Gundapaneni, M. B. Sultan, D. J. Keohane & J. H. Schwartz. (2017) Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy. European Journal of Neurology 25:3, pages 464-468.
Crossref
Crossref
S. V. Kopishinskaya. (2018) Transthyretin familial amyloid polyneuropathy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 118:10, pages 82.
Crossref
Crossref
David Adams, Cécile Cauquil & Céline Labeyrie. (2017) Familial amyloid polyneuropathy. Current Opinion in Neurology 30:5, pages 481-489.
Crossref
Crossref
Joseph D. Schonhoft, Cecilia Monteiro, Lars Plate, Yvonne S. Eisele, John M. Kelly, Daniel Boland, Christopher G. ParkerBenjamin F. Cravatt, Sergio Teruya, Stephen Helmke, Mathew Maurer, John Berk, Yoshiki Sekijima, Marta Novais, Teresa Coelho, Evan T. Powers & Jeffery W. Kelly. (2017) Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. Science Translational Medicine 9:407.
Crossref
Crossref
Jennifer KollmerFelix SahmUte HegenbartJan C. PurruckerChristoph KimmichStefan O. SchönlandErnst HundSabine HeilandJohn M. HayesArnt V. KristenChristoph RöckenMirko PhamMartin BendszusMarkus Weiler. (2017) Sural nerve injury in familial amyloid polyneuropathy. Neurology 89:5, pages 475-484.
Crossref
Crossref
Natalie J. Galant, Per Westermark, Jeffrey N. HigakiAvijit Chakrabartty. (2017) Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy. Clinical Science 131:5, pages 395-409.
Crossref
Crossref
Kate McKeage, Katherine A. Lyseng-Williamson & Lesley J. Scott. (2016) Tafamidis in transthyretin amyloidosis: a guide to its use in delaying peripheral neurological impairment in patients with stage 1 polyneuropathy. Drugs & Therapy Perspectives 33:2, pages 47-53.
Crossref
Crossref
Mona Radwan, Rebecca J. Wood, Xiaojing Sui & Danny M. Hatters. (2017) When proteostasis goes bad: Protein aggregation in the cell. IUBMB Life 69:2, pages 49-54.
Crossref
Crossref
Yoshimichi Miyazaki. (2017) Treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a case report. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 54:1, pages 75-80.
Crossref
Crossref
Marla B Sultan, Balarama Gundapaneni, Jennifer Schumacher & Jeffrey H Schwartz. (2017) Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy. Clinical Medicine Insights: Cardiology 11, pages 117954681773032.
Crossref
Crossref